Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Ottawa

$17,500.00

Characterization of novel bi-specific fusion proteins for the programming of extracellular vesicles for delivery of cytotoxic payloads to hematologic malignancies

FY 2019-20

Summary
"While treatment outcomes for patients with hematological malignancies continue to improve, recurrent disease is often refractory to the traditional chemotherapeutics used in a first line setting. This leaves a gap in the treatment path for these patients. CAR T cell therapy has been a major advancement in filling this gap, achieving complete response rates as high as 88% in recurrent amyloid lymphocytic leukemia. However, the translation of CAR T cell therapy to has been limited by the cost of production and severe adverse events associated with the therapy. CAR T cells rely on the engineering of patient-derived T cells, having to be manufactured on a per patient basis. As an alternative to this therapy, we are developing extracellular vesicles (EVs) which we have programmed to deliver cytotoxic payloads (e.g. granzyme B) to B cell derived cancer cells using single chain variable fragments (scFv) targeting CD19 and CD20 antigens. Our EV-CARs are produced from stable producer cells, allowing us to generate large amounts of EVs in a relatively short timeline. We will validate the specificity of the constructs in vitro, looking both at the binding of the targeting domains, as well as payload uptake in target and non-target cells. The constructs are modular in nature, allowing us to optimize the platform by replacing components. Moving forward, we will also look at in vivo models (e.g. mouse models) to further validate these constructs and collect safety data required for clinical translation. The production process of the EV-CARs will also be optimized for large scale production of clinical-grade EVs.These CAR-T-like EVs (aka EV-CARs), would offer a cheaper, off-the-shelf alternative to the personalized CAR-T cells while avoiding immune-mediated toxicities."
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
429058
Name
Whelan Jack T
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Characterization of novel bi-specific fusion proteins for the programming of extracellular vesicles for delivery of cytotoxic payloads to hematologic malignancies
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Blood Cancer; Car T Cell; Cytotoxicity; Exosomes; Extracellular Vesicles; Immunotherapy; Leukemia; Single Chain Variable Fragments
Abstract
"While treatment outcomes for patients with hematological malignancies continue to improve, recurrent disease is often refractory to the traditional chemotherapeutics used in a first line setting. This leaves a gap in the treatment path for these patients. CAR T cell therapy has been a major advancement in filling this gap, achieving complete response rates as high as 88% in recurrent amyloid lymphocytic leukemia. However, the translation of CAR T cell therapy to has been limited by the cost of production and severe adverse events associated with the therapy. CAR T cells rely on the engineering of patient-derived T cells, having to be manufactured on a per patient basis. As an alternative to this therapy, we are developing extracellular vesicles (EVs) which we have programmed to deliver cytotoxic payloads (e.g. granzyme B) to B cell derived cancer cells using single chain variable fragments (scFv) targeting CD19 and CD20 antigens. Our EV-CARs are produced from stable producer cells, allowing us to generate large amounts of EVs in a relatively short timeline. We will validate the specificity of the constructs in vitro, looking both at the binding of the targeting domains, as well as payload uptake in target and non-target cells. The constructs are modular in nature, allowing us to optimize the platform by replacing components. Moving forward, we will also look at in vivo models (e.g. mouse models) to further validate these constructs and collect safety data required for clinical translation. The production process of the EV-CARs will also be optimized for large scale production of clinical-grade EVs.These CAR-T-like EVs (aka EV-CARs), would offer a cheaper, off-the-shelf alternative to the personalized CAR-T cells while avoiding immune-mediated toxicities."
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Whelan, Jack T
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~